Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TBCC domain containing 1 pseudogene (ENSG00000259099) is classified as a pseudogene, specifically lacking known protein-coding potential or established biological function as a receptor, enzyme, or other canonical drug target class[3][4]. Pseudogenes are genomic DNA sequences similar to normal genes but typically non-functional due to mutations or lack of transcription[4][2]. They can sometimes regulate their protein-coding counterparts by mechanisms such as acting as competitive endogenous RNAs (ceRNAs) or miRNA sponges, affecting gene expression indirectly[1][6], but there is currently no evidence that TBCC domain containing 1 pseudogene plays such a role. Its parent gene, TBCC domain containing 1 (TBCCD1), encodes a centrosomal protein involved in centrosome positioning and internal cell organization, but this function is not attributed to this pseudogene[5]. TBCC domain containing 1 pseudogene is not considered a therapeutic target due to its lack of protein-coding capacity and no known direct biological or disease function[3][4][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TBCC domain containing 1 pseudogene.